Our team of experts brings you cancer-related news, features, and survivor stories.
For the latest news about research we conduct and fund, see ACS Research News.
Published on: June 1, 2023
Follow research highlighted each day in this ongoing meeting by checking out the ASCO News Highlights for People with Cancer blog.
Published on: October 26, 2022
Women who use chemical hair straighteners and relaxers may have a higher risk of uterine cancer, according to a new study from researchers at the US National Institutes of Health (NIH).
Published on: July 2, 2021
The annual scientific and clinical Journal Impact Factors were released on June 30, and the American Cancer Society’s CA: A Cancer Journal for Clinicians outperformed. The CA impact factor climbed from 292.3 last year to a staggering 508.7 and remains the highest-rated oncology journal in the world.
Published on: December 9, 2020
A study using data from the Centers for Disease Control and Prevention (CDC) provides evidence that the human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical precancer – lesions that can become cervical cancer.
Published on: June 18, 2020
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
Published on: June 9, 2020
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or dying from cancer.
Published on: April 29, 2020
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.
Published on: April 22, 2020
The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene.
